Reach Us +1-504-608-2390
Fall In Leukocyte Count For Monitoring Of Immunosuppressive And Anti-cancer Drug Therapy | 56658
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Fall in leukocyte count for monitoring of immunosuppressive and anti-cancer drug therapy

7th Euro-Global Summit on Toxicology & Applied Pharmacology

Frieder Keller

University Hospital Ulm-University of Ulm, Germany

ScientificTracks Abstracts: J Clin Toxicol

DOI: 10.4172/2161-0495.C1.021

Background: The therapeutic window between efficacy on the one side and toxicity on the other side is very narrow for many immunosuppressive, anti-viral and anti-cancer drugs. The present contribution is to review the literature data and our own experience with regard to the value of a leukocyte monitoring for efficient drug therapy. Methods: If there is leukocytopenia at least an effect can be assumed. Since the beneficial effect and the adverse effect are frequently better correlated than the drug concentration and the target effect, monitoring of leukocytes might be more cost-effective than monitoring of drug concentrations. A selective PubMed research was undertaken, therefore, to look for publications where the monitoring of leukocytes is used for targeting the drug dose. Results: The use of cyclophosphamide has been successfully introduced for treatment of systemic vaxculitis by adjusting the dose to the leukocyte count. A leukocyte nadir was found to indicate a better prognosis in lung cancer and testicular cancer patients. A better outcome has been associated with cancer chemotherapy targeting neutropenia than with lower dose. This is in agreement with our own experience on the intravenous cyclophosphamide pulse therapy in IgA nephritis. This regimen applies also to the monitoring of azathioprine or mycophenolate and to ganciclovir and valganciclovir or cidofovir. However, a threshold nadir for leukocyte count must be defined to avoid persistent agranulocytosis. Conclusion: Leukocytopenia is an effect of immunosuppression, of anti-viral or anti-cancer drug therapy. This easy to measure lab parameter can be used for pharmacodynamic monitoring of the efficacy of the critical dose drug therapy.

Frieder Keller has completed his MD and Post-doctoral studies from Free University, Berlin. He was Head of Nephrology Division at Ulm University and is a Teacher in Clinical Medicine. He has published more than 250 papers in PubMed cited journals and is serving as an Editorial Board Member of Clinical Nephrology.

Email: [email protected]